Browse > Article
http://dx.doi.org/10.3904/kjm.2013.84.6.851

A Case of Dyspnea Caused by Local Botulinum Toxin Type A Injection  

So, Hoon Sub (Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Moon, Min Young (Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Lee, Jung Su (Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Kim, Ho Cheol (Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Kang, Byung Chul (Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine)
Koh, Younsuck (Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Publication Information
The Korean Journal of Medicine / v.84, no.6, 2013 , pp. 851-854 More about this Journal
Abstract
Botulinum toxin type A is widely used for functional improvement of muscles and aesthetic plastic surgery. It paralyzes the injected muscle by inhibiting acetylcholine release from synapses of neuromuscular junctions. We herein report a case of progressive respiratory distress after botulinum toxin injection at both the gastrocnemius and soleus muscles. The patient also showed ptosis, dysphonia, dysphagia, and general weakness. Vocal cord dysfunction was observed by laryngoscopy. Other neurologic examination findings, including those of the physical examination, brain MRI, and Jolly's test, were normal. To our knowledge, this is the first report of botulinum toxin injection associated with dyspnea (MRC dyspnea scale, grade 3) in Korea.
Keywords
Botulinum toxin; Type A; Dyspnea;
Citations & Related Records
연도 인용수 순위
  • Reference
1 International Society of Aesthetic Plastic Surgery. ISAPS International Survey on Aesthetic/Cosmetic Procedurse Performed in 2010 [Internet]. Seoul: ISAPS, c2011 [cited 2012 Oct 30]. Available from: http://www.isaps.org/files/ html-contents/ ISAPS-Procedures-Study-Results-2011.pdf.
2 Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm 2008;115:559-565.   DOI   ScienceOn
3 ALLERGAN, BOTOX${\circledR}$ Cosmetic Prescribing Information, in Internet, ALLERGAN, Editor 2011. Avilable from: http:// www.allergan.com/assets/pdf/botox_cosmetic_pi.pdf.
4 Sunness JS, Kelman S. Cosmetic botox injection mimicking myasthenia gravis. Plast Reconstr Surg 2004;113:1515. http://dx.doi.org/10.1097/01.PRS.0000118253.77597.9F.
5 Turkel CC, Bowen B, Liu J, Brin MF. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil 2006;87: 786-792.   DOI   ScienceOn
6 Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004;20:981-990.   DOI   ScienceOn
7 Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984; 76:794-798.   DOI   ScienceOn
8 Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006;354:462-471.   DOI   ScienceOn
9 Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46:840-849.   DOI   ScienceOn